Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
5.28
-0.04 (-0.75%)
Aug 14, 2025, 2:02 PM - Market open
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Entrada Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $25.67, which forecasts a 386.17% increase in the stock price over the next year. The lowest target is $20 and the highest is $29.
Price Target: $25.67 (+386.17%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 20, 2025.
Analyst Ratings
The average analyst rating for Entrada Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +278.79% | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +278.79% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +278.79% | Feb 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +278.79% | Feb 4, 2025 |
| Roth MKM | Roth MKM | Strong Buy Initiates $29 | Strong Buy | Initiates | $29 | +449.24% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
47.72M
from 210.78M
Decreased by -77.36%
Revenue Next Year
34.31M
from 47.72M
Decreased by -28.09%
EPS This Year
-3.23
from 1.68
EPS Next Year
-4.34
from -3.23
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 66.0M | 59.2M | 59.2M | ||
| Avg | 47.7M | 34.3M | 57.5M | ||
| Low | 33.4M | 4.4M | 55.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -68.7% | 24.2% | 72.6% | ||
| Avg | -77.4% | -28.1% | 67.7% | ||
| Low | -84.1% | -90.8% | 61.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.70 | -3.13 | -3.50 |
| Avg | -3.23 | -4.34 | -3.99 |
| Low | -3.58 | -5.00 | -4.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.